UTHR insider exercises 8,000 options; sells 8,000 shares at $423–$437
Rhea-AI Filing Summary
United Therapeutics (UTHR) reporting person Martine A. Rothblatt executed option exercises and share sales under a pre-arranged 10b5-1 trading plan entered May 2, 2025. On 10/01/2025 and 10/02/2025 she exercised a total of 8,000 stock options at an exercise price of $120.26, resulting in acquisition of 8,000 common shares. Concurrently, the filing discloses sales of a total of 8,000 common shares executed in multiple trades with weighted-average sale prices reported between $423.305 and $437.70. The 10b5-1 plan will continue until the earlier of exhaustion of a tranche of 294,000 options expiring 03/15/2026 or 12/31/2025. The report also discloses significant indirect holdings via spouse and family trusts, including trusts holding 324,518, 258,117, 45,596, and 15,962 shares.
Positive
- Use of a pre-arranged 10b5-1 plan provides documented trading authorization and timing (entered 05/02/2025)
- Option exercises totaling 8,000 shares at a known $120.26 exercise price increased reported beneficial ownership in a transparent manner
- Filing discloses clear termination conditions for the plan: exhaustion of a 294,000 tranche or 12/31/2025
Negative
- Reporting person sold 8,000 shares in market transactions at weighted-average prices between approximately $423 and $437, representing net disposition activity
- Significant concentration of indirect holdings via family trusts (e.g., 324,518 and 258,117 shares) could affect governance dynamics
Insights
Insider exercised 8,000 options and sold 8,000 shares under a 10b5-1 plan.
The filing shows synchronized option exercise and stock sales on 10/01/2025 and 10/02/2025, executed pursuant to a pre-arranged 10b5-1 plan. The exercises were at an exercise price of $120.26, and sales occurred at weighted-average prices ranging from roughly $423 to $437.
This pattern is consistent with plan-driven liquidity events rather than ad-hoc trading; the filing explicitly states the plan's termination triggers (exhaustion of a 294,000 tranche or 12/31/2025), which are monitorable milestones.
Report discloses material indirect holdings and planned option tranche expiry.
The report lists substantial indirect holdings in family trusts totaling over 643,000 shares across named trusts and additional holdings by spouse, indicating concentrated family ownership influence. The filing also documents that a tranche of 294,000 options expires on 03/15/2026, an explicit timeline for potential further option exercises or plan activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 2,000 | $433.0625 | $866K |
| Sale | Common Stock | 2,000 | $436.70 | $873K |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,080 | $423.3225 | $457K |
| Sale | Common Stock | 2,076 | $426.0155 | $884K |
| Sale | Common Stock | 844 | $426.7773 | $360K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $423.305 to $423.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $425.55 to $426.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $426.70 to $426.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $432.885 to $433.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $436.70 to $437.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
